• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar

Enabling Statisticians to Lead through Innovation and Excellence

    Enabling Statisticians to Lead through Innovation and Excellence

Search The Effective Statistician

  • Winning with Words and Graphs: The Effective Statistician presentation and data visualization masterclass
  • How to be an effective statistician
  • Start here!
  • Podcast
    • PSI Careers
  • Free resources on visualization
    • Recording available: Flatten the curve – learnings from COVID-19 visualizations to better explore and communicate your data
  • Free resources on influencing
    • The Effective Statistician Leadership Program
    • Recording available: It’s not enough to be right!
  • Join The Effective Statistician LinkedIn group
  • Quick tips to be more effective
  • Legal disclosure – about us
    • Datenschutzerklärung – sorry, still in German…
You are here: Home / Innovation / Introduction to Benefit-Risk Assessment

Introduction to Benefit-Risk Assessment

By Alexander on 2019-03-19 0

Introduction to Benefit-Risk Assessment
  • share 
  • tweet  
  • share  
  • share 
  • save  

Interview with Maria Costa and Shahrul Mt-Isa

Benefit-risk assessments are made by various stakeholders including sponsors, regulators, payers, physicians, and patients throughout the life-cycle of a treatment.

The understanding of data plays a vital role in weighting positive and negative effects of medications.

In this episode, we give you an introduction to what benefit-risk (BR) assessment is in order for you to understand your role.

We also cover the following topics:

  • What are the different situations, where BR becomes important?
  • What is the difference between qualitative and quantitative BR assessments?
  • Which relevant parties work on this topic?
  • What are good resources to get started with BR and how will they help?
  • What would you recommend as further readings and how can I get additional training?
  • What is the BR SIG doing and how to become a member?

About Maria Costa

Dr Maria Costa completed her PhD in Statistics at Warwick University in 2008 where she worked on developing new approaches for generalized additive and survival models using penalized spline functions. Dr Costa then became a Research Fellow at the Warwick Systems Biology Centre working on the connection between the circadian clock of plants and global warming as part of the ROBuST project.

Dr Costa has worked in the pharmaceutical industry since 2013, starting at GlaxoSmithKline R&D where she focused on developing methodology for quantitative Benefit-Risk assessment, as well as providing statistical consultancy on complex clinical trial designs to multiple projects across R&D. Since 2018 Dr Costa has joined Novartis Pharma as an Associate Director in Biostatistics.

Dr Costa is interested in the fields of benefit-risk assessment, Bayesian inference, adaptive designs, probability of success.

About Shahrul Mt-Isa

Dr Shahrul Mt-Isa is a Principal Scientist in the Health Technology Assessment (HTA) Statistics research group under the MSD Research Laboratories (MRL) Biostatistics and Research Decision Sciences (BARDS) organisation. He is responsible for statistical analyses in clinical study portfolios in antiviral, antibacterial, and oncology indications to support HTA dossiers submission globally.

He co-leads the MRL Benefit-Risk (BR) Strategic Initiative to innovate and implement novel methodologies and processes for BR Assessment. Externally, he is an active member of the EFPSI BR and HTA Special Interest Groups.

Prior to joining MSD, he was the Deputy Public Lead in the IMI-PROTECT BR Work Package (WP5) while serving as an academic statistician at the School of Public Health, Imperial College London, where he currently holds an Honorary Fellowship.

References

Click here to get to the pre-conference course of PSI 2019!

Click here to access the homepage of the BR SIG!

Read the aims of the SIG on the PSI homepage!

Link to a replay of the webinar about IMI PREFER and patient preferences!

Bayesian joint modelling of benefit and risk in drug development

The Case for a Bayesian Approach to Benefit-Risk Assessment:: Overview and Future Directions

Never miss an episode of The Effective Statistician

Join hundreds of your peers and subscribe to get our latest updates by email!

Get the shownotes of our podcast episodes plus tips and tricks to increase your impact at work to boost your career!

Success! Now check your email to confirm your subscription.

There was an error submitting your subscription. Please try again.

We won't send you spam. Unsubscribe at any time. Powered by ConvertKit
  • share 
  • tweet  
  • share  
  • share 
  • save  

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Primary Sidebar

Join the PSI newsletter here!

Categories

  • Excellence
  • Innovation
  • Knowledge
  • Leadership
  • PSI Calc Podcast

Recent Posts

  • Extrapolation to paedriatics
  • How to integrate external data into your clinical studies: from theory to application
  • A preview into the PSI conference
  • Patient-reported outcomes and the FDA Patient-Focused Drug Development Guidance
  • Apps on prescription paid by the government

Archives

  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • December 2021
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • March 2021
  • February 2021
  • January 2021
  • December 2020
  • November 2020
  • October 2020
  • September 2020
  • August 2020
  • July 2020
  • June 2020
  • May 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
  • December 2019
  • November 2019
  • October 2019
  • September 2019
  • August 2019
  • July 2019
  • June 2019
  • May 2019
  • April 2019
  • March 2019
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • September 2018
  • August 2018
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018

The podcast is run in association with PSI

Copyright © 2022 · Smart Passive Income Pro on Genesis Framework · WordPress · Log in